Uptake of environmental toxicants by the locus ceruleus: A potential trigger for neurodegenerative, demyelinating and psychiatric disorders

Medical Hypotheses

Volumn 82, Issue 1, 2014, Pages 97-104

  Pamphlett, Roger ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; MERCURY; NEUROMELANIN; NORADRENALIN;

ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DEPRESSION; ENVIRONMENTAL EXPOSURE; HUMAN; LOCUS CERULEUS; MAJOR DEPRESSION; MENTAL DISEASE; MICROVASCULATURE; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; STRESS;

DEMYELINATING DISEASES; HAZARDOUS SUBSTANCES; HUMANS; LOCUS COERULEUS; MENTAL DISORDERS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NOREPINEPHRINE;

EID: 84890862647     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.11.016     Document Type: Article

References (96)

1. Marien M.R., Colpaert F.C., Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Rev 2004, 45:38-78.
2. Polak P.E., Kalinin S., Feinstein D.L. Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2011, 134:665-677.
3. Ordway G.A. Neuropathology of central norepinephrine in psychiatric disorders: postmortem research. Brain norepinephrine neurobiology and therapeutics 2007, 341-362. Cambridge University Press, Cambridge. G.A. Ordway, M.A. Schwartz, A. Frazer (Eds.).
4. Ross S.B., Johansson J.G., Lindborg B., Dahlbom R. Cyclizing compounds. I. Tertiary N-(2-bromobenzyl)-N-haloalkylamines with adrenergic blocking action. Acta Pharm Suec 1973, 10:29-42.
5. Pamphlett R, Kum Jew S. Uptake of inorganic mercury by human locus ceruleus and corticomotor neurons: implications for amyotrophic lateral sclerosis, Acta Neuropathol Commun 2013;1:13.
6. Kvetnansky R., Sabban E.L., Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev 2009, 89:535-606.
7. Benarroch E.E. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 2009, 73:1699-1704.
8. O'Donnell J., Zeppenfeld D., McConnell E., Pena S., Nedergaard M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem Res 2012, 37:2496-2512.
9. Szabadi E. Functional neuroanatomy of the central noradrenergic system. J Psychopharmacol 2013, 27:659-693.
10. Bridges C.C., Zalups R.K. Molecular and ionic mimicry and the transport of toxic metals. Toxicol Appl Pharmacol 2005, 204:274-308.
11. Cohen Z., Molinatti G., Hamel E. Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J Cereb Blood Flow Metab 1997, 17:894-904.
12. Aston-Jones G., Cohen J.D. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 2005, 28:403-450.
13. Pardridge W.M. Blood-brain barrier biology and methodology. J Neurovirol 1999, 5:556-569.
14. Kalinin S., Feinstein D.L., Xu H.L., Huesa G., Pelligrino D.A., Galea E. Degeneration of noradrenergic fibres from the locus coeruleus causes tight-junction disorganisation in the rat brain. Eur J Neurosci 2006, 24:3393-3400.
15. Toussay X., Basu K., Lacoste B., Hamel E. Locus coeruleus stimulation recruits a broad cortical neuronal network and increases cortical perfusion. J Neurosci 2013, 33:3390-3401.
16. Davis H., Guo X., Lambert S., Stancescu M., Hickman J.J. Small molecule induction of human umbilical stem cells into MBP-positive oligodendrocytes in a defined three-dimensional environment. ACS Chem Neurosci 2012, 3:31-39.
17. Double K.L., Dedov V.N., Fedorow H., Kettle E., Halliday G.M., Garner B., et al. The comparative biology of neuromelanin and lipofuscin in the human brain. Cell Mol Life Sci 2008, 65:1669-1682.
18. Zecca L., Bellei C., Costi P., Albertini A., Monzani E., Casella L., et al. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc Natl Acad Sci USA 2008, 105:17567-17572.
19. Siso S., Hanzlicek D., Fluehmann G., Kathmann I., Tomek A., Papa V., et al. Neurodegenerative diseases in domestic animals: a comparative review. Vet J 2006, 171:20-38.
20. Jaim-Etcheverry G. 2-Chloroethylamines (DSP4 and xylamine). Toxic actions on noradrenergic neurons. Highly selective neurotoxins: basic and clinical applications 1998, 131-140. Humana Press Inc., Totowa, NJ. R.M. Kostrzewa (Ed.).
21. Barresi M., Ciurleo R., Giacoppo S., Foti Cuzzola V., Celi D., Bramanti P., et al. Evaluation of olfactory dysfunction in neurodegenerative diseases. J Neurol Sci 2012, 323:16-24.
22. Shipley M.T., Halloran F.J., de la Torre J. Surprisingly rich projection from locus coeruleus to the olfactory bulb in the rat. Brain Res 1985, 329:294-299.
23. Manaye K.F., McIntire D.D., Mann D.M., German D.C. Locus coeruleus cell loss in the aging human brain: a non-random process. J Comp Neurol 1995, 358:79-87.
24. Braak H., Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011, 121:171-181.
25. Harvey L., Boksa P. Prenatal and postnatal animal models of immune activation: relevance to a range of neurodevelopmental disorders. Dev Neurobiol 2012, 72:1335-1348.
26. Fernandes de Abreu D.A., Landel V., Feron F. Seasonal, gestational and postnatal influences on multiple sclerosis: the beneficial role of a vitamin D supplementation during early life. J Neurol Sci 2011, 311:64-68.
27. Cavanagh J.B. Long term persistence of mercury in the brain. Br J Ind Med 1988, 45:649-651.
28. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003, 60:337-341.
29. Srinivasan J., Schmidt W.J. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. Behav Brain Res 2004, 151:191-199.
30. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992, 32:667-676.
31. Marcyniuk B., Mann D.M., Yates P.O. Loss of nerve cells from locus coeruleus in Alzheimer's disease is topographically arranged. Neurosci Lett 1986, 64:247-252.
32. Mann D.M., Yates P.O., Hawkes J. The pathology of the human locus ceruleus. Clin Neuropathol 1983, 2:1-7.
33. Hodges J. Familial frontotemporal dementia and amyotrophic lateral sclerosis associated with the C9ORF72 hexanucleotide repeat. Brain 2012, 135:652-655.
34. Konradi C., Sillivan S.E., Clay H.B. Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol Dis 2012, 45:37-47.
35. Szot P. Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system. Epilepsia 2012, 53(Suppl. 1):61-66.
36. Altshuler L.L., Abulseoud O.A., Foland-Ross L., Bartzokis G., Chang S., Mintz J., et al. Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord 2010, 12:541-549.
37. Rajkowska G., Stockmeier C.A. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 2013, 14:1225-1236.
38. Qiu C., von Strauss E., Backman L., Winblad B., Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013, 80:1888-1894.
39. Pamphlett R. Exposure to environmental toxins and the risk of sporadic motor neuron disease: an expanded Australian case-control study. Eur J Neurol 2012, 19:1343-1348.
40. Beck R.W., Trobe J.D., Moke P.S., Gal R.L., Xing D.Y., Bhatti M.T., et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol-Chic 2003, 121:944-949.
41. Lincoln J., Milner P., Appenzeller O., Burnstock G., Qualls C. Innervation of normal human sural and optic nerves by noradrenaline- and peptide-containing nervi vasorum and nervorum: effect of diabetes and alcoholism. Brain Res 1993, 632:48-56.
42. Tellioglu T., Robertson D. Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications. Expert Rev Mol Med 2001, 2001:1-10.
43. Morahan J.M., Yu B., Trent R.J., Pamphlett R. Genetic susceptibility to environmental toxicants in ALS. Am J Med Genet B Neuropsychiatr Genet 2007, 144:885-890.
44. Mann D.M.A. Neuronal loss in old people: the affects of aging or disease?. Neurobiol Aging 1987, 8:550-551.
45. Pamphlett R., Waley P. Mercury in human spinal motor neurons. Acta Neuropathol 1998, 96:515-519.
46. Zeevi N., Pachter J., McCullough L.D., Wolfson L., Kuchel G.A. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc 2010, 58:1749-1757.
47. Cannon J.R., Greenamyre J.T. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci 2011, 124:225-250.
48. Danscher G., Moller-Madsen B. Silver amplification of mercury sulfide and selenide: a histochemical method for light and electron microscopic localization of mercury in tissue. J Histochem Cytochem 1985, 33:219-228.
49. Hackett M.J., McQuillan J.A., El-Assaad F., Aitken J.B., Levina A., Cohen D.D., et al. Chemical alterations to murine brain tissue induced by formalin fixation: implications for biospectroscopic imaging and mapping studies of disease pathogenesis. Analyst 2011, 136:2941-2952.
50. Hoffmann D., Hoffmann I., El-Bayoumy K. The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 2001, 14:767-790.
51. Ritchie G.D., Still K.R., Alexander W.K., Nordholm A.F., Wilson C.L., Rossi J., et al. A review of the neurotoxicity risk of selected hydrocarbon fuels. J Toxicol Environ Health B Crit Rev 2001, 4:223-312.
52. Bourassa M.W., Miller L.M. Metal imaging in neurodegenerative diseases. Metallomics 2012, 4:721-738.
53. Lee J., Siegele R., Pastuovic Z., Hackett M.J., Hunt N.H., Grau G.E., et al. Light and heavy ion beam analysis of thin biological sections. Nucl Instrum Meth B 2013, 306:129-133.
54. Tshala-Katumbay D.D., Spencer P.S. Chapter 18 toxic disorders of the upper motor neuron system. Handb Clin Neurol 2007, 82:353-372.
55. Keren N.I., Lozar C.T., Harris K.C., Morgan P.S., Eckert M.A. In vivo mapping of the human locus coeruleus. Neuroimage 2009, 47:1261-1267.
56. Chamberlain S.R., Robbins T.W. Noradrenergic modulation of cognition: therapeutic implications. J Psychopharmacol 2013, 27:694-718.
57. LeWitt P.A. Norepinephrine: the next therapeutics frontier for Parkinson's disease. Transl Neurodegener 2012, 1:4.
58. Bertel O., Malessa S., Sluga E., Hornykiewicz O. Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Res 1991, 566:54-60.
59. Ressler K.J., Nemeroff C.B. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectr 2001, 6:663-666.
60. Ewan K.B., Pamphlett R. Increased inorganic mercury in spinal motor neurons following chelating agents. Neurotoxicology 1996, 17:343-349.
61. Haglund M., Sjobeck M., Englund E. Locus ceruleus degeneration is ubiquitous in Alzheimer's disease: possible implications for diagnosis and treatment. Neuropathology 2006, 26:528-532.
62. Heneka M.T., Nadrigny F., Regen T., Martinez-Hernandez A., Dumitrescu-Ozimek L., Terwel D., et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 2010, 107:6058-6063.
63. Mutter J., Curth A., Naumann J., Deth R., Walach H. Does inorganic mercury play a role in Alzheimer's disease? A systematic review and an integrated molecular mechanism. J Alzheimers Dis 2010, 22:357-374.
64. Johansson L., Guo X., Waern M., Ostling S., Gustafson D., Bengtsson C., et al. Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain 2010, 133:2217-2224.
65. Farkas E., De Jong G.I., de Vos R.A.I., Steur E.N.H.J., Luiten P.G.M. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathologica 2000, 100:395-402.
66. Wyss-Coray T., Rogers J. Inflammation in Alzheimer disease - a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012, 2:a006346.
67. Del Tredici K., Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry 2013, 84:774-783.
68. Delaville C., Navailles S., Benazzouz A. Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism. Neuroscience 2012, 202:424-433.
69. Bjorkblom B., Adilbayeva A., Maple-Grodem J., Piston D., Okvist M., Xu X.M., et al. The Parkinson's disease protein DJ-1 binds metals and protects against metal induced cytotoxicity. J Biol Chem 2013, 288:22809-22820.
70. Clark A.J., Ritz B., Prescott E., Rod N.H. Psychosocial risk factors, pre-motor symptoms and first-time hospitalization with Parkinson's disease: a prospective cohort study. Eur J Neurol 2013, 20:1113-1120.
71. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Mol Neurobiol 2013, http://dx.doi.org/10.1007/s12035-013-8483-x.
72. Deleidi M., Gasser T. The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci 2013, 70:4259-4273.
73. Okamoto K., Kihira T., Kondo T., Kobashi G., Washio M., Sasaki S., et al. Lifestyle factors and risk of amyotrophic lateral sclerosis: a case-control study in Japan. Ann Epidemiol 2009, 19:359-364.
74. Winkler E.A., Sengillo J.D., Sullivan J.S., Henkel J.S., Appel S.H., Zlokovic B.V. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol 2013, 125:111-120.
75. Evans M.C., Couch Y., Sibson N., Turner M.R. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013, 53:34-41.
76. Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci 2013, 16:571-579.
77. Attar A.M., Kharkhaneh A., Etemadifar M., Keyhanian K., Davoudi V., Saadatnia M. Serum mercury level and multiple sclerosis. Biol Trace Elem Res 2012, 146:150-153.
78. Artemiadis A.K., Anagnostouli M.C., Alexopoulos E.C. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 2011, 36:109-120.
79. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003, 9:540-549.
80. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013, 333:1-4.
81. Hertz L., Chen Y., Gibbs M.E., Zang P., Peng L. Astrocytic adrenoceptors: a major drug target in neurological and psychiatric disorders?. Curr Drug Targets CNS Neurol Disord 2004, 3:239-267.
82. Gao Z., Tsirka S.E. Animal models of MS reveal multiple roles of microglia in disease pathogenesis. Neurol Res Int 2011, 2011:383087.
83. Chandley MJ, Ordway GA. Noradrenergic dysfunction in depression and suicide. In: Dwivedi Y, editor. The neurobiological basis of suicide. Boca Raton (FL): CRC Press; 2012. p. chapter 3.
84. Kobal Grum D., Kobal A.B., Arneric N., Horvat M., Zenko B., Dzeroski S., et al. Personality traits in miners with past occupational elemental mercury exposure. Environ Health Perspect 2006, 114:290-296.
85. Hosang G.M., Korszun A., Jones L., Jones I., McGuffin P., Farmer A.E. Life-event specificity: bipolar disorder compared with unipolar depression. Br J Psychiatry 2012, 201:458-465.
86. Rajkowska G., Hughes J., Stockmeier C.A., Miguel-Hidalgo J.J., Maciag D. Coverage of blood vessels by astrocytic endfeet is reduced in major depressive disorder. Biol Psychiatry 2013, 73:613-621.
87. Makhija K., Karunakaran S. The role of inflammatory cytokines on the aetiopathogenesis of depression. Aust N Z J Psychiatry 2013, 47:828-839.
88. Bowley M.P., Drevets W.C., Ongur D., Price J.L. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002, 52:404-412.
89. Frick L.R., Williams K., Pittenger C. Microglial dysregulation in psychiatric disease. Clin Dev Immunol 2013, 2013:608654.
90. Vostrikov V., Uranova N. Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders. Schizophr Res Treat 2011, 2011:174689.
91. Berridge C.W., Dunn A.J. DSP-4-induced depletion of brain norepinephrine produces opposite effects on exploratory behavior 3 and 14 days after treatment. Psychopharmacology 1990, 100:504-508.
92. Kanofsky J.D., Rosen W.A., Ryan P.B., Decina P., Fieve R.R., Kanofsky P.B. Lead levels in the hair of bipolar patients and normal controls. Med Hypotheses 1986, 20:151-155.
93. Bender R.E., Alloy L.B. Life stress and kindling in bipolar disorder: review of the evidence and integration with emerging biopsychosocial theories. Clin Psychol Rev 2011, 31:383-398.
94. Gaillard J.M., Tissot R. Blood-brain movements of tryptophan and tyrosine in manic-depressive illness and schizophrenia. J Neural Transm Suppl 1979, 189-196.
95. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35:804-817.
96. Hamidi M., Drevets W.C., Price J.L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004, 55:563-569.